Faruqi & Faruqi, LLP: Investigating Potential Claims Against Geron Corporation
Faruqi & Faruqi, LLP, a renowned securities law firm, is currently investigating potential claims against Geron Corporation (Geron or the Company) following significant losses suffered by investors between February 28, 2024, and February 25, 2025. The firm encourages investors who have incurred losses exceeding $100,000 during this period to contact Partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Background
Geron is a biotechnology company specializing in the discovery and development of therapeutics for cancer and aging. Over the specified period, the Company made several announcements regarding its clinical trials and regulatory developments that have raised concerns among investors. These announcements, among others, may have influenced the Company’s stock price and resulted in substantial losses for some investors.
Investigation and Deadline
Faruqi & Faruqi is investigating the Company’s actions during this period to determine whether Geron and certain of its executives and directors violated federal securities laws. The firm is also reminding investors of the May 12, 2025, deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Geron.
Impact on Individual Investors
If you have suffered significant losses exceeding $100,000 during the aforementioned period, you may be entitled to compensation. Contacting Faruqi & Faruqi partner Josh Wilson directly can help you understand your legal rights and potential remedies. The investigation may lead to a class action lawsuit, which could result in recovering your losses and potentially other damages as well.
Impact on the World
The investigation into Geron’s actions may serve as a reminder to other publicly traded companies to ensure transparency and accuracy in their communications with investors. Such events can lead to increased scrutiny from regulatory bodies, shareholder activism, and potential changes in corporate governance policies. Additionally, the outcome of this investigation could set a precedent for future securities class action lawsuits.
Conclusion
Investors who have suffered significant losses in Geron between February 28, 2024, and February 25, 2025, are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly to discuss their legal rights and potential remedies. The investigation into Geron’s actions could have far-reaching implications for the biotechnology industry and the securities market as a whole. Stay informed and protect your investments.
- Contact Faruqi & Faruqi partner Josh Wilson for information on your legal rights: 877-247-4292 or 212-983-9330 (Ext. 1310)
- Investigation focuses on potential violations of federal securities laws during the specified period
- May 12, 2025, is the deadline to seek the role of lead plaintiff in a federal securities class action
- Individual investors may be entitled to compensation
- Outcome of the investigation could have implications for the biotechnology industry and securities market
